Daisuke Nakata

Daisuke Nakata

Auto-generated profile, based on publicly available information

Daisuke Nakata

Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KMKazuhiro Miwa
Kazuhiro Miwa
THTakenori Hitaka
Takenori Hitaka
TITakashi Imada
Takashi Imada
SSSatoshi Sasaki
Satoshi Sasaki
MYMie Yoshimatsu
Mie Yoshimatsu
TKTomoyuki Kitazaki
Tomoyuki Kitazaki

16 May 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
KIKenichi Iwai
Kenichi Iwai
MYMasahiro Yaguchi
Masahiro Yaguchi
KNKazuho Nishimura
Kazuho Nishimura
YYYukiko Yamamoto
Yukiko Yamamoto
TTToshiya Tamura
Toshiya Tamura
TNToshiyuki Nomura
Toshiyuki Nomura
The modulation of pre‐mRNA splicing is proposed as an attractive anti‐neoplastic strategy, especially for the cancers that exhibit aberrant pre‐mRNA splicing. Here, we discovered that T‐025 functions as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs), evolutionally conserved kinases that facilitate exon recognition in the splicing machinery. Treatment with T‐025 reduced CLK‐dependent phosphorylation, resulting in the induction of skipped exons, cell death, and growth suppression in vitro and in vivo . Further, through growth inhibitory characterization, we identified high CLK2 expression or MYC amplification as a sensitive‐associated biomarker of T‐025. Mechanistically, the level of CLK2 expression correlated with the magnitude of global skipped exons in response to T‐025 treatment. MYC activation, which altered pre‐mRNA splicing without the transcriptional regulation of CLKs, rendered cancer cells vulnerable to CLK inhibitors with synergistic cell death. Finally, we demonstrated in vivo anti‐tumor efficacy of T‐025 in an allograft model of spontaneous, MYC‐driven breast cancer, at well‐tolerated dosage. Collectively, our results suggest that the novel CLK inhibitor could have therapeutic benefits, especially for MYC‐driven cancer patients.

1 January 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DNDaisuke Nakata
Daisuke Nakata
SNShoichi Nakao
Shoichi Nakao
KNKazuhide Nakayama
Kazuhide Nakayama
SAShinsuke Araki
Shinsuke Araki
YNYusuke Nakayama
Yusuke Nakayama
ANAtsushi Nakanishi
Atsushi Nakanishi

1 January 2014 in European Journal of Pharmacology
Verified
Journal Article
Closed access
DNDaisuke Nakata
Daisuke Nakata
TMTsuneo Masaki
Tsuneo Masaki
ATAkira Tanaka
Akira Tanaka
MYMie Yoshimatsu
Mie Yoshimatsu
YAYumiko Akinaga
Yumiko Akinaga
MKMasami Kusaka
Masami Kusaka

1 April 2003 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
KTKazue Takahata
Kazue Takahata
HKHiroshi Katsuki
Hiroshi Katsuki
TKToshiaki Kume
Toshiaki Kume
DNDaisuke Nakata
Daisuke Nakata
KIKen Ito
Ken Ito
AAAkinori Akaike
Akinori Akaike
Purpose. To investigate the neurotoxic outcome in the rat retina exposed to nitric oxide (NO) released from an NO donor and to evaluate the effects of neurotrophic factors on the survival of NO-damaged retinal cells. methods. An NO releasing compound, N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino) ethanamine (NOC 12), was intravitreously injected into a rat’s right eye. The influences of NOC 12 on retinal neurons and the neuroprotective effects of ciliary neurotrophic factor (CNTF) or brain-derived neurotrophic factor (BDNF) on NOC 12–mediated damage were estimated by counting cells in the ganglion cell layer (GCL) and by measuring the thickness of retinal layers. The exact count of retinal ganglion cells (RGCs) was also confirmed by means of retrograde labeling with a fluorescent tracer. results. Morphometric analyses of retinal damage in the NOC 12–exposed eyes demonstrated a significant and dose-dependent decrease in cell density in the GCL and a reduction in thickness of the inner plexiform layer and inner nuclear layer, but not of the outer nuclear layer. TdT-dUTP terminal nick-end labeling of retinal sections after intravitreous injection of NOC 12 demonstrated that NO could trigger apoptotic cell death. The counting of the RGCs labeled with a fluorescent tracer suggested that a decrease in GCL cell density induced by NOC 12 reflects a loss in RGCs. Treatment with CNTF (1 μg) or BDNF (1 μg) before the intravitreous injection of NOC 12 (400 nmol) demonstrated that these trophic factors have protective effects against NO-induced neuronal cell death in the retina. conclusions. Exogenous NO induces retinal neurotoxicity, suggesting that NO plays a pathogenic role in degenerative retinal diseases. BDNF and CNTF protect retinal neurons from NO-mediated neurotoxicity.

6 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
ANAkito Nakamura
Akito Nakamura
DNDaisuke Nakata
Daisuke Nakata
YKYuichi Kakoi
Yuichi Kakoi
MKMihoko Kunitomo
Mihoko Kunitomo
SMSaomi Murai
Saomi Murai
THTakahito Hara
Takahito Hara
CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells